Loading...
XSTO
SENZA
Market cap16mUSD
Jun 25, Last price  
5.38SEK
1D
7.17%
1Q
3.46%
IPO
-86.49%
Name

SenzaGen AB

Chart & Performance

D1W1MN
P/E
—
P/S
2.75
EPS
—
Div Yield, %
—
Shrs. gr., 5y
11.03%
Rev. gr., 5y
84.16%
Revenues
58m
+15.69%
1,624,0001,748,000498,0001,153,0001,997,0002,724,0007,958,00015,422,00041,770,00049,870,00057,695,000
Net income
-18m
L-19.22%
262,000-2,857,000-8,942,000-12,994,000-16,090,000-50,237,000-27,315,000-31,346,000-24,912,000-22,097,000-17,850,000
CFO
-9m
L-43.29%
1,042,999-6,281,000-9,692,000-11,646,000-23,212,000-31,081,000-29,376,000-20,980,000-16,071,000-16,453,000-9,330,000

Profile

SenzaGen AB develops, performs, and sells non-animal tests for assessing a substance's allergenicity. The company offers genomic allergen rapid detection (GARD)skin, an in vitro test to identify potential chemical skin sensitizers; GARDpotency, an in vitro add-on test to GARDskin for potency classification; GARDskin Dose-response, an in vitro test for quantitative skin sensitizing potency assessment of chemicals; and GARDair, an in vitro test for identifying chemical respiratory sensitizers, as well as GARDskin medical device, an in vitro skin sensitization testing for medical devices and solid materials. It also provides irritation and corrosion testing services. The company offers services through license partners and distributors. It has a collaboration agreement with the Research Institute for Fragrance Materials to develop tests for photosensitization. The company was incorporated in 2010 and is headquartered in Lund, Sweden.
URL
https://senzagen.com/
IPO date
Sep 21, 2017
Employees
35
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
57,695
15.69%
49,870
19.39%
41,770
170.85%
Cost of revenue
70,501
64,610
62,446
Unusual Expense (Income)
NOPBT
(12,806)
(14,740)
(20,676)
NOPBT Margin
Operating Taxes
(511)
121
(50)
Tax Rate
NOPAT
(12,295)
(14,861)
(20,626)
Net income
(17,850)
-19.22%
(22,097)
-11.30%
(24,912)
-20.53%
Dividends
Dividend yield
Proceeds from repurchase of equity
37,210
(42)
BB yield
-19.76%
0.01%
Debt
Debt current
(99)
Long-term debt
1,781
1,673
1,207
Deferred revenue
Other long-term liabilities
10,093
(1,207)
Net debt
(37,827)
(15,951)
(38,868)
Cash flow
Cash from operating activities
(9,330)
(16,453)
(16,071)
CAPEX
(4,531)
(129)
(2,589)
Cash from investing activities
(4,248)
(6,082)
(13,437)
Cash from financing activities
35,469
147
31
FCF
(21,656)
(14,097)
(19,971)
Balance
Cash
39,608
17,624
39,976
Long term investments
Excess cash
36,723
15,130
37,888
Stockholders' equity
67,553
88,780
Invested Capital
98,515
54,150
52,510
ROIC
ROCE
EV
Common stock shares outstanding
27,289
24,188
24,085
Price
6.90
-5.22%
7.28
-39.59%
12.05
20.50%
Market cap
188,294
6.93%
176,089
-39.33%
290,230
20.60%
EV
150,467
160,138
251,362
EBITDA
(12,806)
(6,554)
(11,256)
EV/EBITDA
Interest
477
37
46
Interest/NOPBT